Anastassia Negrouk
Overview
Explore the profile of Anastassia Negrouk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
224
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tarwid J, Childs M, Junod-Moser D, Negrouk A, Egondi T, Tipple C
BMJ Open
. 2025 Jan;
14(12):e078862.
PMID: 39806656
Introduction: The Drugs for Neglected Diseases initiative (DNDi) is committed to maximising the scientific value of the individual participant data (IPD) it has collected during its 20 years of activity...
2.
Lalova-Spinks T, De Sutter E, Valcke P, Kindt E, Lejeune S, Negrouk A, et al.
Front Med (Lausanne)
. 2022 Oct;
9:995689.
PMID: 36300179
Background: The COVID-19 pandemic brought global disruption to health, society and economy, including to the conduct of clinical research. In the European Union (EU), the legal and ethical framework for...
3.
De Sutter E, Lalova-Spinks T, Borry P, Valcke P, Kindt E, Negrouk A, et al.
Front Med (Lausanne)
. 2022 Oct;
9:995688.
PMID: 36237540
Background: Owing to the infectious nature of COVID-19, alternative solutions, such as electronic informed consent (eIC), needed to be implemented to inform research participants about study-related information and to obtain...
4.
Lalova T, Negrouk A, Deleersnijder A, Valcke P, Huys I
Eur J Health Law
. 2021 Mar;
27(5):425-450.
PMID: 33652387
The COVID-19 pandemic has severely disrupted non-coronavirus clinical trials. In the case of life-threatening diseases, such as cancer, this is particularly dangerous, as treatment cannot simply be stopped. In the...
5.
Lalova T, Padeanu C, Negrouk A, Lacombe D, Geissler J, Klingmann I, et al.
Front Med (Lausanne)
. 2020 Nov;
7:585722.
PMID: 33195343
To analyze the current situation of cross-border access to clinical trials in the EU with an overview of stakeholders' real-life experience, and to identify the needs, challenges, and potential for...
6.
Stahel R, Lacombe D, Cardoso F, Casali P, Negrouk A, Marais R, et al.
ESMO Open
. 2020 Mar;
5(2).
PMID: 32213534
Background: The academia-industry interface is important, and, despite challenges that inevitably occur, bears the potential for positive synergies to emerge. Perceived barriers to wider collaboration in academia-industry oncology research in...
7.
Horgan D, Smand C, Negrouk A, Lacombe D
Biomed Hub
. 2020 Jan;
2(Suppl 1):55-62.
PMID: 31988935
Integrating personalised medicine into Europe's healthcare systems will undoubtedly need to draw upon diverse talents via a multi-stakeholder approach taking expertise from academia, industry, healthcare organisations, government, policymakers and, of...
8.
Bagnoli M, Shi T, Gourley C, Speiser P, Reuss A, Nijman H, et al.
Cells
. 2019 Mar;
8(3).
PMID: 30813545
In the era of personalized medicine, the introduction of translational studies in clinical trials has substantially increased their costs, but provides the possibility of improving the productivity of trials with...
9.
Negrouk A, Lacombe D
Lancet Oncol
. 2018 Oct;
19(10):1278-1280.
PMID: 30303112
No abstract available.
10.
Negrouk A, Lacombe D, Cardoso F, Morin F, Carrasco E, Maurel J, et al.
ESMO Open
. 2017 Oct;
2(3):e000187.
PMID: 29021919
Cancer is a complex disease that is constantly evolving. It is now the most common cause of death in Europe after cardiovascular diseases. There are inequalities among European countries, potentially...